Clinical readout
Single dose of CIDEB siRNA cuts liver fat up to 80% in MASLD trial
In a first-in-human study of 40 people, one dose of the CIDEB-targeting siRNA lowered liver fat by 58% to 80% at week 36, depending on dose, versus 2.9% on placebo. Liver fat returned to normal in 62% of treated participants. The candidate is moving into later-stage trials, and Regeneron will review its MASH pipeline on November 10.
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.